Seroatlas · Human Serome Atlas

KRT5

Keratin, type II cytoskeletal 5

Also known as: CK-5, EBS2, K2C5_HUMAN, KRT5A

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P13647
Gene: KRT5
Ensembl: ENSG00000186081
Chromosome: 12
Canonical length: 590 aa
Protein class: Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location: Intermediate filaments

OverviewNCBI Gene

The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the basal layer of the epidermis with family member KRT14. Mutations in these genes have been associated with a complex of diseases termed epidermolysis bullosa simplex. The type II cytokeratins are clustered in a region of chromosome 12q12-q13. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

590 residues, UniProt reviewed canonical sequence.

>P13647|KRT5
     1  MSRQSSVSFR SGGSRSFSTA SAITPSVSRT SFTSVSRSGG GGGGGFGRVS LAGACGVGGY
    61  GSRSLYNLGG SKRISISTSG GSFRNRFGAG AGGGYGFGGG AGSGFGFGGG AGGGFGLGGG
   121  AGFGGGFGGP GFPVCPPGGI QEVTVNQSLL TPLNLQIDPS IQRVRTEERE QIKTLNNKFA
   181  SFIDKVRFLE QQNKVLDTKW TLLQEQGTKT VRQNLEPLFE QYINNLRRQL DSIVGERGRL
   241  DSELRNMQDL VEDFKNKYED EINKRTTAEN EFVMLKKDVD AAYMNKVELE AKVDALMDEI
   301  NFMKMFFDAE LSQMQTHVSD TSVVLSMDNN RNLDLDSIIA EVKAQYEEIA NRSRTEAESW
   361  YQTKYEELQQ TAGRHGDDLR NTKHEISEMN RMIQRLRAEI DNVKKQCANL QNAIADAEQR
   421  GELALKDARN KLAELEEALQ KAKQDMARLL REYQELMNTK LALDVEIATY RKLLEGEECR
   481  LSGEGVGPVN ISVVTSSVSS GYGSGSGYGG GLGGGLGGGL GGGLAGGSSG SYYSSSSGGV
   541  GLGGGLSVGG SGFSASSGRG LGVGFGSGGG SSSSVKFVST TSSSRKSFKS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against KRT5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.6
Highest tissue expression: 6,496 nTPM

Expression across tissuesHPA

Tissue

esophagus: 6,496 nTPM
skin: 5,567 nTPM
vagina: 2,417 nTPM
cervix: 2,250 nTPM
salivary gland: 989 nTPM
tonsil: 608 nTPM

Single-cell type

esophageal basal cells: 12,162 nCPM
esophageal suprabasal cells: 8,166 nCPM
basal keratinocytes: 7,750 nCPM
ocular epithelial cells: 6,624 nCPM
suprabasal keratinocytes: 3,359 nCPM
esophageal apical cells: 1,434 nCPM

Immune cell

plasmacytoid DC: 33 nTPM
total PBMC: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

choroid plexus: 130 nTPM
hippocampal formation: 3.7 nTPM
basal ganglia: 1.8 nTPM
cerebellum: 1.5 nTPM
cerebral cortex: 1.2 nTPM
thalamus: 1.2 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about KRT5.

Disease | AllUniProt

Conditions KRT5 is implicated in, by any mechanism.

Epidermolysis bullosa simplex 2A, generalized severe (EBS2A) MIM:619555
Epidermolysis bullosa simplex 2B, generalized intermediate (EBS2B) MIM:619588
Epidermolysis bullosa simplex 2C, localized (EBS2C) MIM:619594
Epidermolysis bullosa simplex 2D, generalized, intermediate or severe, autosomal recessive (EBS2D) MIM:619599
Epidermolysis bullosa simplex 2E, with migratory circinate erythema (EBS2E) MIM:609352
Epidermolysis bullosa simplex 2F, with mottled pigmentation (EBS2F) MIM:131960
Dowling-Degos disease 1 (DDD1) MIM:179850

Disease | GeneticClinVar

95 pathogenic / likely-pathogenic of 397 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Epidermolysis bullosa simplex
KRT5-related disorder
Epidermolysis bullosa simplex 2B, generalized intermediate
Epidermolysis bullosa simplex 2C, localized
Epidermolysis bullosa simplex 2A, generalized severe

Disease | ImmuneIEDB

Conditions an epitope on KRT5 was assayed in.

1-chloro-2 T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.44
gnomAD pLI: 0.64
gnomAD missense Z: 0.23
DepMap mean gene effect: -0.07
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of KRT5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads KRT5 as an antibody target. Whether an autoantibody or antibody against KRT5 could matter depends on whether native KRT5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

KRT5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label KRT5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...